Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or RefractoryCD22-expressing B Cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs JCAR 018 (Primary)
- Indications Acute lymphoblastic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 16 Nov 2017 Status changed from suspended to recruiting.
- 02 Nov 2017 Status changed from recruiting to suspended.
- 01 Nov 2017 According to a Juno Therapeutics media release, results of this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting 2017.